NASDAQ · STAA

STAAR Surgical Company

Healthcare · Medical - Instruments & Supplies

$20.57▼ 3.17% ($0.67)today

As of 10:24 AM ET

52-week

$15.59$35.87

Market cap

$1.02B

P/E

What the market price implies · Reverse DCF

Historical revenue grew by 0.96%/yr over the past 4 years.

Selected forecast · Base scenario

19%/yr · actual 10-year annualized revenue growth

Year 1 growth: 36.45%

Market-implied · Base operating assumptions + edited margins

Unavailable · flat 10-year annualized revenue growth

Reverse DCF solves revenue growth itself using Base operating assumptions and your edited margins. Changing forecast growth alone does not change the implied rate. This is a model-implied requirement, not an analyst forecast.

No supported revenue growth rate matches this price with these operating assumptions.

Valuation

Recommended · Revenue & margin DCF

Price used

$20.57

Estimated value / share

Unavailable

Base scenario

USD · TTM ending 2026-07-03

More than 85% of this valuation sits in the terminal value beyond year 10, so the result is driven by the perpetuity assumption rather than the projected decade. The valuation is not shown.

Latest quarterly growth differs materially from the latest annual pace. It remains an observed growth input; review whether acceleration or a change in the business explains it.

Year 1 growth 36.45% · Ending margin 10.32% · Discount rate 11.71%

Assumption scenarios, not statistical confidence intervals.

Method, dates & sources

Estimated from future revenue, operating margins, and the investment needed to support them.

Price timestamp: Sep 18, 2026, 2:24 PM UTC
Financial statement period: TTM ending 2026-07-03
Data refreshed: Sep 18, 2026, 2:24 PM UTC · provider

Why this method?

There is not a stable run of positive FCFF to anchor a direct cash-flow CAGR, so the model should start from revenue and margin assumptions instead.

Is FCFF positive and has it been for 3+ consecutive years? Latest FCFF is not positive.

Price vs Fundamentals

Why The Stock Is Moving

Likely multiple compressionHigh confidence

1Y Price: -19.55%Revenue (TTM): 51.3%FCF (TTM): 84.57%P/E: 64th pct

What changed

The stock fell 19.55% over the last year. Revenue grew 51.3% over the trailing twelve months. Operating margin moved from -48.83% to 10.32%. Free cash flow grew 84.57% over the trailing twelve months.

What the market seems to be pricing

Visible fundamentals weakened far less than the stock price. The market appears to be discounting durability, risk, or trust rather than just the latest reported numbers.

What would invalidate this read

This read changes if operating margin (currently 10.32%) continues to decline, or if revenue growth turns negative. The bull case requires the business to hold its current trajectory.

Performance

Return analysis

Company profile

STAAR Surgical Company, along with its subsidiaries, specializes in ophthalmological solutions, focusing on the design, development, manufacturing, and commercialization of implantable lenses for vision correction, complete with the sophisticated delivery systems necessary for their implantation.

CEOWarren Foust

SectorHealthcare

IndustryMedical - Instruments & Supplies

Employees921

IPO dateFeb 24, 1992

https://www.staar.com

Market multiples

Forward P/E—

EV/EBITDA-14.35

Enterprise value$1.06B

Stock splits

May 18, 1992↓ Reverse

Every 2 shares became 1

-50%

Nov 1, 1990↓ Reverse

Every 2 shares became 1

-50%

Nov 9, 1984↑ Forward

Every 1 shares became 2

+100%

Jul 3, 1984↑ Forward

Every 1 shares became 2

+100%

Profitability & growth

Revenue growth111.04%

Gross margin (FY2025)76.19%▼0.1ppvs FY2024

Operating margin (FY2025)-19.19%▼15.2ppvs FY2024

ROE1.09%▲22.8ppvs FY2025

Analyst consensus

RatingHold

Target price$31.50▲53.16%

Buy

Hold

Sell

Analyst ratings tend to be lagging indicators. Use as one signal among many.

Earnings

Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.

Next report

Nov 4, 2026

Q4 FY26 · EPS est $0.20 · Revenue est $79.1M

View

NASDAQ · STAA

STAAR Surgical Company

Healthcare · Medical - Instruments & Supplies

$20.57▼ 3.17% ($0.67)today

As of 10:24 AM ET

52-week

$15.59$35.87

Market cap

$1.02B

P/E

What the market price implies · Reverse DCF

Historical revenue grew by 0.96%/yr over the past 4 years.

Selected forecast · Base scenario

19%/yr · actual 10-year annualized revenue growth

Year 1 growth: 36.45%

Market-implied · Base operating assumptions + edited margins

Unavailable · flat 10-year annualized revenue growth

No supported revenue growth rate matches this price with these operating assumptions.

Valuation

Recommended · Revenue & margin DCF

Price used

$20.57

Estimated value / share

Unavailable

Base scenario

USD · TTM ending 2026-07-03

More than 85% of this valuation sits in the terminal value beyond year 10, so the result is driven by the perpetuity assumption rather than the projected decade. The valuation is not shown.

Latest quarterly growth differs materially from the latest annual pace. It remains an observed growth input; review whether acceleration or a change in the business explains it.

Year 1 growth 36.45% · Ending margin 10.32% · Discount rate 11.71%

Assumption scenarios, not statistical confidence intervals.

Method, dates & sources

Estimated from future revenue, operating margins, and the investment needed to support them.

Price timestamp: Sep 18, 2026, 2:24 PM UTC
Financial statement period: TTM ending 2026-07-03
Data refreshed: Sep 18, 2026, 2:24 PM UTC · provider

Why this method?

There is not a stable run of positive FCFF to anchor a direct cash-flow CAGR, so the model should start from revenue and margin assumptions instead.

Is FCFF positive and has it been for 3+ consecutive years? Latest FCFF is not positive.

Price vs Fundamentals

Why The Stock Is Moving

Likely multiple compressionHigh confidence

1Y Price: -19.55%Revenue (TTM): 51.3%FCF (TTM): 84.57%P/E: 64th pct

What changed

What the market seems to be pricing

Visible fundamentals weakened far less than the stock price. The market appears to be discounting durability, risk, or trust rather than just the latest reported numbers.

What would invalidate this read

This read changes if operating margin (currently 10.32%) continues to decline, or if revenue growth turns negative. The bull case requires the business to hold its current trajectory.

Performance

Return analysis

Company profile

CEOWarren Foust

SectorHealthcare

IndustryMedical - Instruments & Supplies

Employees921

IPO dateFeb 24, 1992

https://www.staar.com

Market multiples

Forward P/E—

EV/EBITDA-14.35

Enterprise value$1.06B

Stock splits

May 18, 1992↓ Reverse

Every 2 shares became 1

-50%

Nov 1, 1990↓ Reverse

Every 2 shares became 1

-50%

Nov 9, 1984↑ Forward

Every 1 shares became 2

+100%

Jul 3, 1984↑ Forward

Every 1 shares became 2

+100%

Profitability & growth

Revenue growth111.04%

Gross margin (FY2025)76.19%▼0.1ppvs FY2024

Operating margin (FY2025)-19.19%▼15.2ppvs FY2024

ROE1.09%▲22.8ppvs FY2025

Analyst consensus

RatingHold

Target price$31.50▲53.16%

Buy

Hold

Sell

Analyst ratings tend to be lagging indicators. Use as one signal among many.

Earnings

Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.

Next report

Nov 4, 2026

Q4 FY26 · EPS est $0.20 · Revenue est $79.1M

View